These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15480425)

  • 1. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2004 Nov; 23(54):8766-76. PubMed ID: 15480425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
    Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
    Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
    Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2024 Sep; 43(40):3018. PubMed ID: 39209967
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
    Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
    Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
    Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
    Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    Ishitsuka K; Hideshima T; Neri P; Vallet S; Shiraishi N; Okawa Y; Shen Z; Raje N; Kiziltepe T; Ocio EM; Chauhan D; Tassone P; Munshi N; Campbell RM; Dios AD; Shih C; Starling JJ; Tamura K; Anderson KC
    Br J Haematol; 2008 May; 141(5):598-606. PubMed ID: 18397345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
    Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
    Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
    Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
    Lioni M; Noma K; Snyder A; Klein-Szanto A; Diehl JA; Rustgi AK; Herlyn M; Smalley KS
    Mol Cancer Ther; 2008 Sep; 7(9):2866-75. PubMed ID: 18790767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen LB; Munshi N; Saxena S; Anderson KC
    Apoptosis; 2004 Mar; 9(2):149-55. PubMed ID: 15004512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
    Hideshima T; Mitsiades C; Akiyama M; Hayashi T; Chauhan D; Richardson P; Schlossman R; Podar K; Munshi NC; Mitsiades N; Anderson KC
    Blood; 2003 Feb; 101(4):1530-4. PubMed ID: 12393500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
    Shi YY; Small GW; Orlowski RZ
    Breast Cancer Res Treat; 2006 Nov; 100(1):33-47. PubMed ID: 16807678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
    Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
    J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.